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Abstract The recent discovery of ghrelin, the endogenous li-
gand for the growth hormone secretagogue receptor, is the result
of almost 25 years of research by many groups all around the
world, and represents a milestone in our understanding of
growth hormone secretion and energy homeostasis. This minire-
view is focused on recent studies on ghrelin, pointing out the
cellular and molecular mechanisms involved in the gene expres-
sion of ghrelin since recent studies have unequivocally shown
that ghrelin biological activity is dependent on a peculiar post-
translational processing. Major interest in this peptide derived
from the fact that, in addition to other e¡ects, it is involved in
the regulation of energy balance by inducing weight gain and
reducing fat utilization. These activities are likely mediated by a
CNS network of cells that is also modulated by other hormones
such as leptin. Ghrelin has emerged as a premeal initiation
factor that informs CNS about the status of the energy balance.
The development of ghrelin analogs, agonists and antagonists,
appears as a suitable approach for possible therapeutic interven-
tion in a variety of disease states linked to alterations in body
weight homeostasis.
( 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Ghrelin, the unique orexant gastrointestinal acylated
peptide: isolation, identi¢cation and structures
Ghrelin was discovered at the end of 1999 [1] as the endog-
enous ligand for the growth hormone secretagogue receptor
(GHS-R); GHSs are a group of synthetic compounds with the
ability to induce growth hormone secretion in all species
tested to date [2]. Ghrelin identi¢cation represents a brilliant
result on how to search endogenous ligands with the use of
the orphan receptor strategy. In the last years research aimed
to identify novel ligands using orphan G protein-coupled re-
ceptor (GPCR)-expressing cells have resulted in the discovery
of several novel bioactive peptides such as orexins, prolactin
releasing peptide and many others. Unlike other orphan re-
ceptors, GHS-R is known to bind arti¢cial compounds with
growth hormone secretagogue activity such as GHRP-6 or
hexarelin, supplying a suitable positive control for the assay
used to identify the endogenous ligand. In order to identify
the ligand for GHS-R, a cultured cell line transfected and
expressing the receptor was established and used to identify
tissue extracts that produced a classical intracelullar Ca2þ in-
crease. By screening several tissues, a very strong activity was
unexpectedly found in stomach extracts. The active peptide
was puri¢ed by gel ¢ltration, ion exchange, and reverse liquid
chromatography and its sequence determined by Edman deg-
radation. To note, an expressed sequence tag clone, contain-
ing the coding region of the peptide, revealed that the third
residue was a serine, which was then con¢rmed in cDNA
clones encoding the peptide precursor isolated from a rat
stomach cDNA library. Initially, a synthetic peptide based
on the cDNA sequence was synthesized and compared to
puri¢ed natural ghrelin. This comparison revealed that the
synthetic peptide, unlike the puri¢ed protein, did not increase
intracellular calcium, had a retention time in high-perfor-
mance liquid chromatography (HPLC) shorter than that of
natural peptide and, intriguingly, its molecular mass was
126 atomic mass units (amu) smaller than natural peptide.
Further studies demonstrated that the di¡erence in mass
was due to an esteri¢cation of serine 3 with an n-octanoic
acid. The mature 28-amino acid peptide is cleaved from its
precursor preproghrelin and is characterized by a very pecu-
liar structural modi¢cation, since the hydroxyl group of serine
in position 3 is covalently acylated by an n-octanoic acid res-
idue, although other types of acylations (10 carbon fatty acid
group with and without insaturations) have been observed
[1,3,4]. Although the acylation mechanism is not fully ad-
dressed, it is reasonable that it is necessary for crossing the
blood^brain barrier; at any rate, this uniqueness has potential
therapeutic implications for ghrelin blockade, since an antag-
onist to the putative transacylation enzyme that octanoylates
ghrelin should inactivate this hormone in a very selective man-
ner. This biochemical post-translational modi¢cation is the
¢rst observed in peptides isolated from natural sources and
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is postulated to be crucial for the biological activity of the
peptide, although acyl modi¢cation has been seen in G pro-
teins and receptors, which are conjugated to myristoyl acid
(C14) or palmitoyl acid (C16) [5]. Intriguingly, short frag-
ments encompassing the ¢rst four to ¢ve residues of ghrelin
(with intact acylated serine) were able to activate signal trans-
duction of ghrelin receptor (GHS-R type a). In addition, a
mechanism of alternative splicing of the ghrelin gene origi-
nates an analogous peptide except for the glutamine in posi-
tion 14 that is missing [6]. This deletion results from the use of
the CAG codon, which encodes Gln14 as a splicing signal.
Thus, two types of active ghrelin peptide are produced in rat
stomach, ghrelin and des-Gln14-ghrelin. The activity of both
ghrelins is the same. However, des-Gln14-ghrelin is only
present in low amounts in the stomach, indicating that ghrelin
is the major active form. Finally, the testis-speci¢c expression
of another species of the ghrelin gene transcript in mice, called
ghrelin gene-derived transcript (GGDT) has been reported.
GGDT is not expressed in the stomach, only in testis, and
the sequence acting as the unique exon is located at intron 3
of the ghrelin gene, indicating that it is generated by alterna-
tive usage of this intron as a testis-speci¢c exon, for yielding a
12 amino acid peptide [7].
2. Tissue distribution and regulation
Ghrelin is produced prevalently in the stomach by the X/A-
like cells within the oxyntic glands of the gastric fundus mu-
cosa [8], although minor amounts are present elsewhere in the
body. The placenta [9], testis [10], kidney [11], pituitary [12],
small intestine [13], pancreas [14], lymphocytes [15], brain [16],
lung [17] and ovary [18,19] also express signi¢cant levels of
ghrelin. At any rate, two-thirds of plasma ghrelin levels comes
from the stomach, and at least one-third from the small in-
testine [20]. The ubiquitous expression of ghrelin in a host of
tissues is suggestive of local paracrine and/or autocrine ac-
tions. Thus, it has been found that ghrelin regulates testicular
steroidogenesis and testosterone secretion by the Leydig cells
[21]. In addition, ghrelin inhibits the expression of stem cell
factor (SCF, the major stimulator of germ cell development)
in staged rat seminiferous tubules ([22] and M. Tena-Sampere,
personal unpublished communication). In keeping with an
important paracrine role for ghrelin in gonadal development,
it has been shown that ghrelin inhibits development of mouse
pre-implantation embryos [23], while it is noticeable that SCF
had been found to be involved in mouse blastocyst implanta-
tion. For instance, ghrelin has been found in placenta [9], an
organ that contain all the main regulatory elements of the
somatotropic axis, i.e. GH, GHRH, somatostatin and IGF-
1; in spite of the existance of a speci¢c pro¢le of expression of
ghrelin mRNA throughout pregnancy, the physiological func-
tion of ghrelin in this organ is not fully known at present,
although very recently it has been reported that ghrelin is
involved in the decidualization of human endometrial stromal
cells [24]. Ghrelin expression is up-regulated in rodents after
fasting, hypoglycemia or leptin administration [25], and it is
strongly increased by chronic undernutrition in animal models
[26], suggesting that ghrelin expression and secretion are en-
hanced in situations of negative energy balance. In addition,
in experimental conditions of negative energy balance, such as
streptozotocin-induced diabetes in rats, preproghrelin mRNA
expression and ghrelin secretion are strongly enhanced [27].
Caloric intake or chronically positive energy balance suppress
ghrelin expression and secretion. Intriguingly, in pregnancy, a
hypermetabolic condition characterized by increase in mater-
nal body fat and weight, gastric ghrelin mRNA, as well as
plasmatic levels, do not change. These data indicate that in-
creased food intake in pregnancy is unlikely to be mediated by
increased ghrelin gene expression. In contrast, but in keeping
with data obtained in non-pregnant animals, food restriction
during pregnancy also led to increased ghrelin gene expres-
sion, suggesting a sort of adaptive response to prevent the
long-lasting alterations associated with undernutrition [26].
Plasma ghrelin levels are speci¢cally modulated also in exper-
imental models of in£ammatory cachexia as well as in patients
with rheumatoid arthritis, a degenerative systemic in£amma-
tion often associated with alterations in body weight homeo-
stasis. Surprisingly, in experimental arthritis in rats, there is a
compensatory variation of ghrelin levels that relates to body
weight adjustments. Plasma ghrelin levels decrease during the
¢rst part of the chronic in£ammation together with body
weight, while a recovery of ghrelin levels, together with an
increase in body weight, in the latter stage suggests an adap-
tive response and may represent a compensatory mechanism
under catabolic conditions. It is noteworthy that, in rheuma-
toid arthritis patients, a chronic imbalance in ghrelin levels
has been observed, suggesting that this gastric hormone may
participate, together with other factors, in alterations of met-
abolic status during in£ammatory stress (O. Gualillo, personal
unplished communication). In addition, no gender-based dif-
ferences in circulating ghrelin have been shown in humans [28]
and similarly, gender does not alter ghrelin mRNA expression
in rats [29].
3. Mechanism of action
Ghrelin was puri¢ed using the receptor for the synthetic
GH-secretagogue MK-0677 (so called GHS-R1a), so it is ob-
vious that ghrelin must operate through it. There is an on-
going controversy about whether the cloned secretagogue re-
ceptor is ‘the’ receptor or just ‘one of the’ receptors for that
family of compounds. Di¡erences in the binding activities of
the di¡erent peptidic (GHRP-6, ghrelin) and non-peptidyl
(MK-0677) molecules have been reported [30]. Further sup-
port for the existence of several receptors derives from de-
tailed studies using hexarelin as tracer. However, the fact
that KO mice for the cloned GHS-R are unresponsive to
ghrelin in terms of GH secretion and food intake indicates
that at least these two functions are mediated by GHS-R type
1a [31]. Although there is little doubt that the e¡ects of
GHRH and ghrelin on the somatotroph are mediated through
di¡erent receptors, the possible interaction among both recep-
tors is of great interest and has recently been studied. It was
reported that activation of the GHS receptor alone had no
e¡ect on cAMP production, while the coactivation of the
GHS and GHRH receptors produced a cAMP response ap-
proximately twice that observed after activation of the GHRH
receptor alone. This potentiated response is dose-dependent
with respect to both GHRH and GHS, it also depends on
the expression of both receptors, and was observed with a
variety of peptide and non-peptide GHS compounds as well
as with ghrelin. Pharmacological inhibition of signaling mol-
ecules associated with GHS-receptor activation, including G
protein LQ-subunits, phospholipase C, and protein kinase C
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(PKC), had no e¡ect on GHS potentiation of GHRH-induced
cAMP production. Importantly, the potentiation appears to
be selective for the GHRH receptor. Treatment of cells with
forskolin elevated cAMP levels, but these levels were not fur-
ther increased by GHS-receptor activation. Similarly, activa-
tion of two receptors homologous to the GHRH receptor, the
vasoactive intestinal peptide and secretin receptors, increased
cAMP levels, but these levels were not further increased by
GHS-receptor activation [30]. Based on these ¢ndings, it is
possible that direct interactions between GHRH and GHS
receptors may explain the observed e¡ects on signal transduc-
tion.
4. Biological action
Ghrelin possesses a strongly dose-related growth hormone-
releasing e¡ect both in vitro and in vivo; although initially its
GH secretagogue action was likely speci¢c in cultured pitui-
tary cells, ghrelin administration in vivo also a¡ects adreno-
corticotropic hormone, cortisol, prolactin, and aldosterone
levels [32^34]. Intriguingly, co-administration of ghrelin and
GHRH resulted in a signi¢cant synergistic e¡ect on GH se-
cretion but not on ACTH or prolactin secretion. The presence
of GHS-R in the somatotrophs [2], together with the fact that
ghrelin increases in vitro GH secretion, leaves little doubt that
ghrelin acts directly at the pituitary level. Nevertheless, the
fact that ghrelin is much more potent in vivo than in vitro,
and that the GH response to ghrelin is impaired in patients
with hypothalamus^pituitary disconnection, indicates that, in
terms of GH secretion, its major role is exerted at the hypo-
thalamic level [35]. However, it is possible that ghrelin exerts
other e¡ects on somatotroph cell function independently of its
e¡ects on GH secretion. In this regard, it has been shown that
ghrelin in£uences the expression of the transcription factor
Pit-1. [36]. This factor is transcribed in a highly restricted
manner in the anterior pituitary gland, and is responsible
for the somatotroph cell-speci¢c expression of the GH gene.
By a combination of Northern and Western blot analyses, it
was found that ghrelin elicits a time- and dose-dependent
activation of Pit-1 expression in monolayer cultures of infant
rat anterior pituitary cells. The e¡ect was blocked by pretreat-
ment with actimomycin D but not by cycloheximide, suggest-
ing that this action was due to direct transcriptional activation
of Pit-1. Further assessment of the responsive regions of the
Pit-1 promoter showed that the e¡ect of ghrelin takes place in
a sequence that contains two cAMP-responsive elements
(CREs) and that both of them are needed to induce the tran-
scriptional activation of this gene. Although the transducing
pathways that mediate this e¡ect of ghrelin are not yet fully
understood, preliminary evidence suggests that it is dependent
on PKC, mitogen-activated protein kinase (MAPK) and pro-
tein kinase A (PKA) activation [37,38]. Taking into account
the important role played by Pit-1 in somatotroph cell di¡er-
entiation and cell proliferation, these data indicate that ghre-
lin, in addition to its e¡ects on GH secretion, may play an
important role in the physiological control and physiopatho-
logical alterations related to somatotroph cell function. Be-
sides the strong GH-releasing activity, ghrelin has other sig-
ni¢cant actions, including: (1) orexigenic action coupled with
control of energy homeostasis, (2) control of acid secretion
and gastric motility [38], (3) in£uences on pancreatic activity
[39,40], (4) in£uences on sleep [41], (5) cardiovascular actions
[42], and (6) antiproliferative e¡ects on several cell lineages
[43]. In spite of the plethora of physiological actions exerted
by ghrelin, here we focus prevalently on the role of ghrelin as
endogenous feeding signal and its relationships with the so-
phisticated system controlling food intake and body weight
homeostasis.
Fig. 1. Diagrammatic representation of the central and peripheral circuits that in£uence ghrelin expression and mechanism of action.
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5. Ghrelin as orexigenic factor: Molecular and cellular
pathways
Apart from its role in the regulation of somatotrophic cell
function and growth hormone secretion, several studies have
unequivocally shown that ghrelin is strongly involved in the
regulation of energy homeostasis. These studies, in agreement
with previous reports on the orexigenic e¡ects of synthetic
ghrelin analogs, received a powerful boost after the report
that, in rodents, ghrelin stimulates food intake while reducing
fat depot utilization [44]. These ¢ndings have been con¢rmed
by other groups, indicating the involvement of this new hor-
mone in the regulation of energy balance (Fig. 1). Ghrelin
stimulates food intake in rodents, as well as in humans, by
an activity that occurs through mechanisms other than those
implicated in growth hormone regulation [45,46]. Ghrelin is
able to elicit its orexigenic e¡ect when administered by any
route, either centrally or peripherally, a relevant observation
considering that other orexigenic peptides are devoid of action
via the periphery. Ghrelin increases the expression of mRNA
for Agouti-related protein (AgRP) and neuropeptide Y (NPY)
[47] and triggers the expression of immediate early-response
genes in the medial arcuate nucleus of the hypothalamus, an
area rich in NPY and AgRP neurons [48^50]. Intriguingly,
synthetic ghrelin analogs are able to induce potent orexigenic
e¡ects in NPY null mice (NPY3/3) arguing for a major role
of AgRP [51]. In addition, competitive blockade of AGRP
action by melanocortin-receptor agonist MT-II prevented
ghrelin analog-induced weight gain in Npy(3/3) mice, sug-
gesting that chronic peripheral treatment with a ghrelin recep-
tor agonist induces a positive energy balance leading to fat
gain also in the absence of NPY and that these e¡ects could
be mediated in part by AGRP. The in£uences of ghrelin in the
hypothalamus are likely to be opposite to those exerted by
leptin [52^55]. In addition, very recently Yamanaka et al., [56]
have shown that ghrelin directly activates a population of
isolated orexin neurons by depolarization with increases in
action potential frequency. Circulating ghrelin, as well as
ghrelin-containing neurons, may in part mediate activation
of orexin neurons such as that occurring during food restric-
tion. Induction of food intake by ghrelin, which counteracts
reduction in body weight, may be mediated in part by orexins,
which also induce food intake pharmacologically. The stan-
dard hormonal model of ghrelin action asserts that circulating
ghrelin, derived prevalently from the gastrointestinal tract,
accesses the arcuate nucleus of the hypothalamus through a
leaky blood^brain barrier at that location, and increases food
intake by activating NPY/AgRP neurons. Recent evidence has
indicated that at least part of the e¡ect of ghrelin on energy
homeostasis in the hypothalamus might be of intrinsic origin.
Cowley et al. showed that ghrelin is expressed in a previously
uncharacterized group of neurons in the hypothalamus. These
neurons lie in the space between the lateral, arcuate, ventro-
medial, dorsomedial and paraventricular hypothalamic nuclei,
and they send projections to several of these nuclei as well as
outside the hypothalamus [57]. Intringuingly, this area over-
laps with the projections from the suprachiasmatic nucleus,
which might allow the production of ghrelin to be directly
modulated by the circadian clock. Recent ¢ndings give a
clue to what hypothalamic ghrelin does: it is likely that ghre-
lin-positive neurons are closely apposed to the axon terminals
of NPY neurons, raising the possibility that ghrelin is able to
presynaptically modulate the release of NPY and GABA (Q-
aminobutyric acid), by increasing the activity of the NPY-
containing neurons and hyperpolarizing pro-opiomelanocor-
tin (POMC)-containing neurons in the arcuate. It is clear that
the demonstration of an endogenous ghrelin system in the
hypothalamus might shed light on several obscure aspects
that have been associated with the concept that ghrelin from
the stomach acts on hypothalamic nuclei to regulate energy
homeostasis. Clearly, if more work con¢rms the function of
hypothalamic ghrelin, it will represent a very important step
in our understanding of how such complex interactions be-
tween the brain and the gastrointestinal system regulate food
intake and energy expenditure.
6. Conclusions
Ghrelin is a 28 amino acid peptide, predominantly pro-
duced by the stomach, showing a unique structure with an
n-octanoyl ester at its third serine residue, which is essential
for its potent stimulatory activity on somatotroph secretion.
In fact, it has been demonstrated that ghrelin speci¢cally stim-
ulates GH secretion from both rat pituitary cells in culture
and rats in vivo. It displays strong growth hormone-releasing
activity mediated by the hypothalamus^pituitary GH secreta-
gogue receptors that have been found to be speci¢c for a
family of synthetic, orally active GH secretagogues. The dis-
covery of ghrelin brings us to a new understanding of the
regulation of GH secretion. However, ghrelin is much more
than simply a natural GH secretagogue. It also acts on other
central and peripheral receptors and exhibits other actions,
including stimulation of lactotroph and corticotroph secre-
tion, orexigenic, in£uences gastroenteropancreatic functions,
and has metabolic, cardiovascular and antiproliferative ef-
fects. Knowledge of the whole spectrum of the biochemical
mechanisms involved in ghrelin synthesis and secretion will
provide new understanding of the cell biology related to
post-translational regulation of gene expression. This could
help in the design of novel analogs, acting as agonists or
antagonists, which in turn could become candidate drugs for
the treatment of di¡erent pathophysiological conditions asso-
ciated with altered energy balance such as obesity, or cachex-
ia-associated clinical entities.
References
[1] Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H.
and Kangawa, K. (1999) Nature 402, 656^660.
[2] Bowers, C.Y. (1998) Cell. Mol. Life Sci. 54, 1316^1329.
[3] Kojima, M., Hosoda, H., Matsuo, H. and Kangawa, K. (2001)
Trends Endocrinol. Metab. 12, 118^122.
[4] Hosoda, H., Kojima, M., Mizushima, T., Shimizu, S. and Kan-
gawa, K. (2003) J. Biol. Chem. 278, 64^70.
[5] Resh, M.D. (1999) Biochim. Biophys. Acta 1451, 1^16.
[6] Hosoda, H., Kojima, M., Matsuo, H. and Kangawa, K. (2000)
J. Biol. Chem. 275, 21995^22000.
[7] Tanaka, M., Hayashida, Y., Nakao, N., Nakai, N. and Naka-
shima, K. (2001) Biochim. Biophys. Acta 1522, 62^65.
[8] Sakata, I., Nakamura, K., Yamazaki, M., Matsubara, M., Hay-
ashi, Y., Kangawa, K. and Sakai, T. (2002) Peptides 23, 531^
536.
[9] Gualillo, O., Caminos, J., Blanco, M., Garcia-Caballero, T., Ko-
jima, M., Kangawa, K., Dieguez, C. and Casanueva, F. (2001)
Endocrinology 142, 788^794.
[10] Tena-Sempere, M., Barreiro, M.L., Gonzalez, L.C., Gaytan, F.,
Zhang, F.P., Caminos, J.E., Pinilla, L., Casanueva, F.F., Die-
guez, C. and Aguilar, E. (2002) Endocrinology 143, 717^725.
FEBS 27628 11-9-03 Cyaan Magenta Geel Zwart
O. Gualillo et al./FEBS Letters 552 (2003) 105^109108
[11] Mori, K., Yoshimoto, A., Takaya, K., Hosoda, K., Ariyasu, H.,
Yahata, K., Mukoyama, M., Sugawara, A., Hosoda, H., Kojima,
M., Kangawa, K. and Nakao, K. (2000) FEBS Lett. 486, 213^
216.
[12] Korbonits, M., Bustin, S.A., Kojima, M., Jordan, S., Adams,
E.F., Lowe, D.G., Kangawa, K. and Grossman, A.B. (2001)
Clin. Endocrinol. Metab. 86, 881^887.
[13] Date, Y., Kojima, M., Hosoda, H., Sawaguchi, A., Mondal,
M.S., Suganuma, T., Matsukura, S., Kangawa, K. and Nakaza-
to, M. (2000) Endocrinology 141, 4255^4261.
[14] Volante, M., Allia, E., Gugliotta, P., Funaro, A., Broglio, F.,
Deghenghi, R., Muccioli, G., Ghigo, E. and Papotti, M. (2002)
J. Clin. Endocrinol. Metab. 87, 1300^1308.
[15] Hattori, N., Saito, T., Yagyu, T., Jiang, B.H., Kitagawa, K.
and Inagaki, C. (2001) J. Clin. Endocrinol. Metab. 86, 4284^
4291.
[16] Lu, S., Guan, J.L., Wang, Q.P., Uehara, K., Yamada, S., Goto,
N., Date, Y., Nakazato, M., Kojima, M., Kangawa, K. and
Shioda, S. (2002) Neurosci. Lett. 321, 157^160.
[17] Volante, M., Fulcheri, E., Allia, E., Cerrato, M., Pucci, A. and
Papotti, M. (2002) J. Histochem. Cytochem. 50, 1013^1021.
[18] Gaytan, F., Barreiro, M.L., Chopin, L.K., Herington, A.C., Mo-
rales, C., Pinilla, L., Casanueva, F.F., Aguilar, E., Dieguez, C.
and Tena-Sempere, M. (2003) J. Clin. Endocrinol. Metab. 88,
879^887.
[19] Caminos, J.E., Tena-Sempere, M., Gaytan, F., Sanchez-Criado,
J.E., Barreiro, M.L., Nogueiras, R., Casanueva, F.F., Aguilar, E.
and Dieguez, C. (2003) Endocrinology 144, 1594^1602.
[20] Cummings, D.E. and Shannon, M.H. (2003) Arch. Surg. 138,
389^396.
[21] Tena-Sempere, M., Barreiro, M.L., Gonzalez, L.C., Gaytan, F.,
Zhang, F.P., Caminos, J.E., Pinilla, L., Casanueva, F.F., Die-
guez, C. and Aguilar, E. (2002) Endocrinology 143, 717^725.
[22] Tena Sampere, M., personal communication, unpublished.
[23] Kawamura, K., Sato, N., Fukuda, J., Kodama, H., Kumagai, J.,
Tanikawa, H., Nakamura, A., Honda, Y., Sato, T. and Tanaka,
T. (2003) Endocrinology 144, 2623^2633.
[24] Tanaka, K., Minoura, H., Isobe, T., Yonaha, H., Kawato, H.,
Wang, D.F., Yoshida, T., Kojima, M., Kangawa, K. and Toyo-
da, N. (2003) J. Clin. Endocrinol. Metab. 88, 2335^2340.
[25] Toshinai, K., Mondal, M.S., Nakazato, M., Date, Y., Muraka-
mi, N., Kojima, M., Kangawa, K. and Matsukura, S. (2001)
Biochem. Biophys. Res. Commun. 281, 1220^1225.
[26] Gualillo, O., Caminos, J.E., Nogueiras, R., Seoane, L.M., Arvat,
E., Ghigo, E., Casanueva, F.F. and Dieguez, C. (2002) Obes.
Res. 10, 682^687.
[27] Masaoka, T., Suzuki, H., Hosoda, H., Ota, T., Minegishi, Y.,
Nagata, H., Kangawa, K. and Ishii, H. (2003) FEBS Lett. 541,
64^68.
[28] Otto, B., Cuntz, U., Fruehauf, E., Wawarta, R., Folwaczny, C.,
Riepl, R.L., Heiman, M.L., Lehnert, P., Fichter, M. and Tschop,
M. (2001) Eur. J. Endocrinol. 145, 669^673.
[29] Gualillo, O., Caminos, J.E., Kojima, M., Kangawa, K., Arvat,
E., Ghigo, E., Casanueva, F.F. and Dieguez, C. (2001) Eur. J.
Endocrinol. 144, 687^690.
[30] Cassoni, P., Papotti, M., Ghe, C., Catapano, F., Sapino, A.,
Graziani, A., Deghenghi, R., Reissmann, T., Ghigo, E. and Muc-
cioli, G. (2001) J. Clin. Endocrinol. Metab. 86, 1738^1745.
[31] Sun, Y., Wang, P., Zheng, H. and Smith, R.G., 2003. Generation
and characterization of growth hormone secretagogue receptor
knockout mice. Proceedings of the 85th Annual Meeting of the
Endocrine Society, Philadelphia, PA, 2003 (Abstract P1-216).
[32] Cunha, S.R. and Mayo, K.E. (2002) Endocrinology 143, 4570^
4782.
[33] Arvat, E., Maccario, M., Di Vito, L., Broglio, F., Benso, A.,
Gottero, C., Papotti, M., Muccioli, G., Dieguez, C., Casanueva,
F.F., Deghenghi, R., Camanni, F. and Ghigo, E. (2001) J. Clin.
Endocrinol. Metab. 86, 1169^1174.
[34] Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimo-
to, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu,
A., Ogawa, Y., Hosoda, K., Akamizu, T., Kojima, M., Kanga-
wa, K. and Nakao, K. (2000) J. Clin. Endocrinol. Metab. 85,
4908^4911.
[35] Popovic, V., Miljic, D., Micic, D., Damjanovic, S., Arvat, E.,
Ghigo, E., Dieguez, C. and Casanueva, F.F. (2003) J. Clin. En-
docrinol. Metab. 88, 3450^3453.
[36] Garcia, A., Alvarez, C.V., Smith, R.G. and Dieguez, C. (2001)
Mol. Endocrinol. 15, 1484^1495.
[37] Smith, R.G., Gri⁄n, P.R., Xu, Y., Smith, A.G., Liu, K., Cala-
cay, J., Feighner, S.D., Pong, C., Leong, D., Pomes, A., Cheng,
K., Van der Ploeg, L.H., Howard, A.D., Schae¡er, J. and Leo-
nard, R.J. (2000) Biochem. Biophys. Res. Commun. 276, 1306^
1313.
[38] Kohno, D., Gao, H.Z., Muroya, S., Kikuyama, S. and Yada, T.
(2003) Diabetes 52, 948^956.
[39] Masuda, Y., Tanaka, T., Inomata, N., Ohnuma, N., Tanaka, S.,
Itoh, Z., Hosoda, H., Kojima, M. and Kangawa, K. (2000) Bio-
chem. Biophys. Res. Commun. 276, 905^908.
[40] Adeghate, E. and Ponery, A.S. (2002) J. Neuroendocrinol. 14,
555^560.
[41] Reimer, M.K., Pacini, G. and Ahren, B. (2003) Endocrinology
144, 916^921.
[42] Weikel, J.C., Wichniak, A., Ising, M., Brunner, H., Friess, E.,
Held, K., Mathias, S., Schmid, D.A., Uhr, M. and Steiger, A.
(2003) Am. J. Physiol. Endocrinol. Metab. 284, E407^15.
[43] Enomoto, M., Nagaya, N., Uematsu, M., Okumura, H., Naka-
gawa, E., Ono, F., Hosoda, H., Oya, H., Kojima, M., Kanmat-
suse, K. and Kangawa, K., 2003. Clin. Sci. (Lond.), 10.1042/
CS20030184.
[44] Broglio, F., Gottero, C., Arvat, E. and Ghigo, E. (2003) Horm.
Res. 59, 109^117.
[45] Tschop, M., Smiley, D.L. and Heiman, M.L. (2000) Nature 407,
908^913.
[46] Wren, A.M., Small, C.J., Ward, H.L., Murphy, K.G., Dakin,
C.L., Taheri, S., Kennedy, A.R., Roberts, G.H., Morgan,
D.G., Ghatei, M.A. and Bloom, S.R. (2000) Endocrinology
141, 4325^4328.
[47] Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo,
H., Kangawa, K. and Matsukura, S. (2001) Nature 409, 194^198.
[48] Seoane, L.M., Lopez, M., Tovar, S., Casanueva, F.F., Senaris,
R. and Dieguez, C. (2003) Endocrinology 144, 544^551.
[49] Hewson, A.K. and Dickson, S.L. (2000) J. Neuroendocrinol. 12,
1047^1049.
[50] Wang, L., Saint-Pierre, D.H. and Tache, Y. (2002) Neurosci.
Lett. 325, 47^51.
[51] Tung, Y.C., Hewson, A.K. and Dickson, S.L. (2001) J. Neuro-
endocrinol. 13, 209^215.
[52] Tschop, M., Statnick, M.A., Suter, T.M. and Heiman, M.L.
(2002) Endocrinology 143, 558^568.
[53] Horvath, T.L., Diano, S., Sotonyi, P., Heiman, M. and Tschop,
M. (2001) Endocrinology 142, 4163^4169.
[54] Kamegai, J., Tamura, H., Shimizu, T., Ishii, S., Sugihara, H. and
Wakabayashi, I. (2001) Diabetes 50, 2438^2443.
[55] Toshinai, K., Date, Y., Murakami, N., Shimada, M., Mondal,
M.S., Shimbara, T., Guan, J.L., Wang, Q.P., Funahashi, H.,
Sakurai, T., Shioda, S., Matsukura, S., Kangawa, K. and Naka-
zato, M. (2003) Endocrinology 144, 1506^1512.
[56] Yamanaka, A., Beuckmann, C.T., Willie, J.T., Hara, J., Tsujino,
N., Mieda, M., Tominaga, M., Yagami, K., Sugiyama, F., Goto,
K., Yanagisawa, M. and Sakurai, T. (2003) Neuron 38, 701^713.
[57] Cowley, M.A., Smith, R.G., Diano, S., Tschop, M., Pronchuk,
N., Grove, K.L., Strasburger, C.J., Bidlingmaier, M., Esterman,
M., Heiman, M.L., Garcia-Segura, L.M., Nillni, E.A., Mendez,
P., Low, M.J., Sotonyi, P., Friedman, J.M., Liu, H., Pinto, S.,
Colmers, W.F., Cone, R.D. and Horvath, T.L. (2003) Neuron 37,
649^661.
FEBS 27628 11-9-03 Cyaan Magenta Geel Zwart
O. Gualillo et al./FEBS Letters 552 (2003) 105^109 109
